Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.
Auteurs : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F Jaar : 2023 Journal : J Natl Cancer Inst
JCOG0603: Are We Really Sure This Was a Negative Trial?
Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F Jaar : 2022 Journal : J Clin Oncol
Toward Targeted Therapies in Oesophageal Cancers: An Overview.
Auteurs : Bregni G, Beck B Jaar : 2022 Journal : Cancers (Basel)
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.
Auteurs : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A Jaar : 2022 Journal : Cells
Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.
Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F Jaar : 2022 Journal : Curr Opin Oncol